Functional Characterization of Stromal Osteopontin in Melanoma Progression and Metastasis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kumar, Santosh ^a   Sharma, Priyanka ^a   Kumar, Dhiraj ^a   Chakraborty, Goutam ^a,b   Gorain, Mahadeo ^a   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL INTERACTION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CARCINOGENESIS; CELL COMMUNICATION; CELL PROLIFERATION; CELL SEPARATION; DISEASE PROGRESSION; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MITOXANTRONE; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PHENOTYPE; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84880740070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069116     Document Type: Article

References (48)

1. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM, (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82: 539-548.
2. Lee JT, Herlyn M, (2007) Microenvironmental influences in melanoma progression. J Cell Biochem 101: 862-872.
3. Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M, (2011) Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol 21: 83-88.
4. Ruiter D, Bogenrieder T, Elder D, Herlyn M, (2002) Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 3: 35-43.
5. van Kempen LC, van Muijen GN, Ruiter DJ, (2005) Stromal responses in human primary melanoma of the skin. Front Biosci 10: 2922-2931.
6. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
7. Smolle J, Hofmann-Wellenhof R, Fink-Puches R, (1996) Melanoma and stroma: an interaction of biological and prognostic importance. Semin Cutan Med Surg 15: 326-335.
8. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, et al. (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198.
9. Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, et al. (2004) Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci U S A 101: 13756-13761.
10. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS, (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226.
11. Rangaswami H, Bulbule A, Kundu GC, (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87.
12. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, et al. (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830.
13. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC, (2007) Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11: 81-90.
14. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, et al. (2011) Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 15: 1113-1126.
15. Shevde LA, Das S, Clark DW, Samant RS, (2010) Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81.
16. Courter D, Cao H, Kwok S, Kong C, Banh A, et al. (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 5: e9633.
17. Chang PL, Cao M, Hicks P, (2003) Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 24: 1749-1758.
18. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF, (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14: 2037-2044.
19. El-Tanani MK, (2008) Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 13: 4276-4284.
20. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC, (2010) Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31: 192-200.
21. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, et al. (2008) Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Report 1: 641-646.
22. Chakraborty G, Jain S, Kundu GC, (2008) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161.
23. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, et al. (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052.
24. Geissinger E, Weisser C, Fischer P, Schartl M, Wellbrock C, (2002) Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 62: 4820-4828.
25. Rangaswami H, Kundu GC, (2007) Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep 18: 909-915.
26. Rangaswami H, Bulbule A, Kundu GC, (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 279: 38921-38935.
27. Philip S, Bulbule A, Kundu GC, (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276: 44926-44935.
28. Philip S, Kundu GC, (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487-14497.
29. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, et al. (2009) Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114: 49-59.
30. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, et al. (2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201: 1781-1791.
31. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, et al. (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106: 1232-1239.
32. Sumitomo A, Ishino R, Urahama N, Inoue K, Yonezawa K, et al. (2010) The transcriptional mediator subunit MED1/TRAP220 in stromal cells is involved in hematopoietic stem/progenitor cell support through osteopontin expression. Mol Cell Biol 30: 4818-4827.
33. Saika S, Shirai K, Yamanaka O, Miyazaki K, Okada Y, et al. (2007) Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest 87: 130-138.
34. Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, et al. (2009) Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 69: 1230-1239.
35. Luo X, Ruhland MK, Pazolli E, Lind AC, Stewart SA, (2011) Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res 9: 1018-1029.
36. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, et al. (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052.
37. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, et al. (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15: 6939-6946.
38. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC, (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806.
39. Sharma P, Kumar S, Kundu GC, (2010) Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 9: 178.
40. Kumar S, Patil HS, Sharma P, Kumar D, Dasari S, et al. (2012) Andrographolide inhibits Osteopontin expression and breast cancer growth through down regulation of PI3 kinase/Akt signaling pathway. Curr Mol Med 12: 952-966.
41. Chakraborty G, Jain S, Patil TV, Kundu GC, (2008) Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 12: 2305-2318.
42. Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, et al. (2007) Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 101: 979-986.
43. Sun B, Zhang S, Zhao X, Zhang W, Hao X, (2004) Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 25: 1609-1614.
44. Ping YF, Bian XW, (2011) Consice review: Contribution of cancer stem cells to neovascularization. Stem Cells 29: 888-894.
45. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK, (2007) Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26: 4158-4170.
46. Dou J, Wen P, Hu W, Li Y, Wu Y, et al. (2009) Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int 33: 807-815.
47. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, et al. (2001) Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16: 652-659.
48. Ohyama Y, Nemoto H, Rittling S, Tsuji K, Amagasa T, et al. (2004) Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res 19: 1706-1711.